LMB-2(LMB-2) - 药物靶点：IL2RA_专利_临床

概要

基本信息

药物类型

抗体偶联毒素

别名

LMB-2A

靶点

IL2RA

作用方式

抑制剂

作用机制

IL2RA抑制剂(白细胞介素-2受体α链抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [2]

在研适应症-

非在研适应症

急性淋巴细胞白血病成人T细胞白血病/淋巴瘤CD25阳性B细胞慢性淋巴细胞白血病+ [5]

原研机构

National Cancer Institute

在研机构-

非在研机构

National Cancer InstituteNational Institutes of Health Clinical Center

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

8

项与 LMB-2 相关的临床试验

NCT00924170

/ Completed临床1/2期IIT

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

BACKGROUND:
* Cluster of differentiation 25 (CD25) (p55, Tac or interleukin 2 receptor (IL2R) alpha) is strongly expressed in virtually 100% of patients with adult T-cell leukemia/lymphoma (ATL), a highly aggressive human T-lymphotropic virus type 1 (HTLV-1) related malignancy responding poorly to chemotherapy.
* In ATL, the humanized anti-CD25 monoclonal antibody (Mab) daclizumab produced 13-14% responses, and the anti-CD52 Mab Alemtuzumab (Campath-1H) produced response lasting greater than 2 months in 30% of 23 patients.
* LMB-2 is an anti-CD25 recombinant immunotoxin containing variable domains of murine MAb anti-Tac and truncated Pseudomonas exotoxin.
* In a phase I trial at National Cancer Institute (NCI), the maximum tolerated dose (MTD) of LMB-2 was 40 microg/Kg intravenous (IV) given every other day for 3 doses (every other day (QOD) times 3). LMB-2 induced greater than 90% tumor reduction rapidly in all 3 ATL patients on protocol, but achieved only 1 partial response due to rapid tumor progression and/or immunogenicity.
* In preclinical models, response from recombinant immunotoxins is limited by high concentrations of soluble receptor in the blood and especially in the interstitial space of the tumor. Synergism was observed with chemotherapy and immunotoxins, possibly due to reduction of soluble receptor in tumor interstitium.
OBJECTIVES:
-To determine, in nonrandomized fashion, if after verifying its safety, fludarabine and cyclophosphamide (FC) prior to LMB2 for ATL can result in low immunogenicity and a rate of major response lasting greater than 2 months, which may be an improvement over that demonstrated previously from Alemtuzumab (CAMPATH).
Secondary objectives:
* To determine the effect of 1 cycle of FC alone in ATL.
* To examine progression-free and overall survival in ATL after FC/LMB-2.
* Evaluate pharmacokinetics, toxicity, and monitor soluble CD25 and other tumor marker levels in the serum.
* To study the effects of LMB-2 plus FC on normal B- and T-cell subsets by fluorescence-activated cell sorting (FACS).
ELIGIBILITY:
* CD25 plus ATL, untreated or with prior therapy
* Eastern Cooperative Oncology Group (ECOG) 0-2, absolute neutrophil count (ANC), platelets and albumin at least 1000, 75,000, and 3.0.
DESIGN:
* Fludarabine 25 mg/m(2) IV days 1-3
* Cyclophosphamide 250 mg/m(2) IV days 1-3
* LMB-2 30-40 micro g/Kg IV days 3, 5 and 7.
* LMB-2 dose: Begin with 30 microg/Kg times 3. Escalate to 40 microg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 microg/Kg. Continue at 40 microg/Kg if 0-1 of 6 have DLT at 40 microg/Kg.
* Administer cycle 1 with FC alone. Two weeks after starting cycle 1, begin up to 6 cycles of FC plus LMB-2 at minimum 20-day intervals.
* Accrual goals: 29-37 patients, which includes 4 replacements....

开始日期2008-10-31

申办/合作机构

National Cancer Institute

NCT00389506

/ WithdrawnN/AIIT

A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide

RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. LMB-2 immunotoxin can find cancer cells and kill them without harming normal cells. Giving fludarabine and cyclophosphamide followed by LMB-2 immunotoxin may kill more cancer cells.
PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide followed by LMB-2 immunotoxin works in treating patients with Hodgkin's lymphoma.

开始日期2006-09-01

申办/合作机构

National Institutes of Health Clinical Center

[+1]

NCT00321555

/ Completed临床2期IIT

A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia

Background:
* About 80% of patients with hairy cell leukemia (HCL) have tumor cells that have a protein on their surface called cluster of differentiation 25 (CD25).
* The experimental drug LMB-2 is a recombinant immunotoxin that has been shown to kill leukemia and lymphoma cells with the CD25 protein. (A recombinant immunotoxin is a genetically engineered drug that has two parts - a protein that binds or targets a cancer cell, and a toxin that kills the cancer cell to which it binds.)
Objectives:
* To evaluate the safety and effectiveness of LMB-2 in patients with HCL whose cancer cells contain the CD25 protein.
* To evaluate the effects of LMB-2 on the immune system, determine how the drug is metabolized by the body and examine its side effects.
Eligibility:
-Adults with hairy cell leukemia whose tumor cells have CD25 on their surface
Design:
* Up to 27 patients may be included in the study.
* Patients receive an infusion of LMB-2 through a vein every other day for three doses (days 1, 3, 5), constituting one treatment cycle.
* Patients may receive up to six treatment cycles every 4 weeks unless their cancer worsens or they develop unacceptable side effects.
* Blood is drawn weekly for various tests.
* Before each cycle and in follow-up visits, disease status is evaluated with a physical examination, blood tests, chest x-ray and electrocardiogram.
* Before the first cycle, patients may have a computed tomography (CT) scan, echocardiogram (heart ultrasound test) and bone marrow biopsy. With the patient's permission, these tests may be repeated before other cycles also.

开始日期2006-05-02

申办/合作机构

National Cancer Institute

100 项与 LMB-2 相关的临床结果

登录后查看更多信息

100 项与 LMB-2 相关的转化医学

登录后查看更多信息

100 项与 LMB-2 相关的专利（医药）

登录后查看更多信息

20

项与 LMB-2 相关的文献（医药）

2025-07-31·PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

A novel glomerulopathy model demonstrates renal counterbalance via local angiotensin II regulation

Article

作者: KIM, Jun-Dal ; NAGATA, Michio ; MATSUSAKA, Taiji ; SAKAMOTO, Kazuo ; KAWANISHI, Kunio ; TABARA, Saori ; FUKAMIZU, Akiyoshi ; MUROI, Shin-ichi ; KOIZUMI, Masahiro

Renal counterbalance, involving compensatory hypertrophy of the healthy kidney and atrophy of the injured one, remains incompletely understood, particularly at the glomerular level. In this study, we employed NEP25 mice, which selectively express human CD25 in podocytes, enabling precise induction of unilateral podocyte injury through the administration of LMB2, a CD25-targeted immunotoxin. Using a two-kidney, one-nephropathy (2K1N) model, we demonstrated that asymmetric changes in renal blood flow and proteinuria, with histological and transcriptomic analyses uncovering distinct pathological and molecular features between the injured and contralateral healthy kidneys. Notably, an imbalance in intrarenal angiotensin (Ang) II levels was observed, and angiotensin-converting enzyme inhibition ameliorated the glomerular damage and restored perfusion. These findings indicate that local Ang II dysregulation is a key factor in renal counterbalance. Our study provides the first glomerulopathy-based experimental platform to dissect asymmetric renal adaptation, offering fundamental insight into the homeostatic mechanisms of renal function in health and disease.

2019-09-01·Hypertension (Dallas, Tex. : 1979)1区 · 医学

Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner

1区 · 医学

Article

作者: Yanagita, Motoko ; Fujita, Toshiro ; Ueda, Kohei ; Saito, Akihiko ; Fukagawa, Masafumi ; Pastan, Ira ; Nishiyama, Akira ; Niimura, Fumio ; Matsusaka, Taiji ; Koizumi, Masahiro

We have previously shown that podocyte injury increases the glomerular filtration of liver-derived Agt (angiotensinogen) and the generation of intrarenal Ang II (angiotensin II) and that the filtered Agt is reabsorbed by proximal tubules in a manner dependent on megalin. In the present study, we aimed to study the role of megalin in the generation of renal Ang II and sodium handling during nephrotic syndrome. We generated proximal tubule-specific megalin KO (knockout) mice and crossed these animals with NEP25 mice, in which podocyte-specific injury can be induced by injection of the immunotoxin LMB2. Without podocyte injury, renal Agt staining was markedly diminished and urinary Agt increased in KO mice. However, renal Ang II was similar between KO and control mice on average: 117 (95% CI, 101–134) versus 101 (95% CI, 68–133) fmol/g tissue. We next tested the effect of megalin KO on intrarenal Ang II generation with podocyte injury. Control NEP25 mice showed markedly increased renal Agt staining and renal Ang II levels: 450 (336–565) fmol/g tissue. Megalin KO/NEP25 mice showed markedly diminished Agt reabsorption and attenuated renal Ang II: 199 (156–242) fmol/g tissue ( P <0.001). Compared with control NEP25 mice, megalin KO/NEP25 mice excreted 5-fold more sodium in the urine. Western blot analysis showed that megalin KO decreased NHE3 and the cleaved α and γ forms of Epithelial Na Channel. These data indicate that Agt reabsorbed by proximal tubules via megalin in nephrotic syndrome is converted to Ang II, which may contribute to sodium retention and edema formation by activating NHE3 and Epithelial Na Channel.

2017-12-01·Kidney international1区 · 医学

Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury

1区 · 医学

Article

作者: Hai-Chun Yang ; Jun Zou ; Ming-Zhi Zhang ; Jianyong Zhong ; Beom Jin Lim ; Raymond C. Harris ; Taiji Matsusaka ; Agnes B. Fogo ; Ira Pastan ; Jae Won Yang

Chronic glomerular injury is associated with eventual development of tubulointerstitial fibrosis. Here we aimed to assess whether, and how, mild chronic tubulointerstitial injury affects glomeruli. For this, we generated mice expressing different toxin receptors, one on their proximal tubular epithelial cells (diphtheria toxin receptor [DTR]) and the other only on podocytes (human CD25 [IL-2R] driven by the nephrin promoter [Nep25]), allowing serial induction of tubule-specific and glomerular (podocyte)-specific injury, respectively. Six weeks after diphtheria toxin injection, mild interstitial fibrosis was found in Nep25⁺/DTR⁺, but not in Nep25⁺/DTR^- mice. However, atubular glomeruli and neuronal nitric oxide synthase, a mediator of tubuloglomerular feedback, were higher in Nep25⁺/DTR⁺ than in DTR^- mice and these atubular glomeruli had less podocyte density as assessed by WT-1 biomarker expression. Peritubular capillary density, hypoxia-inducible factor-1 and -2, and cyclooxygenase 2 expression were similar at week six in the two groups. At week seven, all mice were given the immunotoxin LMB-2, which binds to CD25 to induce podocyte injury. Ten days later, proteinuria, podocyte injury, and glomerulosclerosis were more severe in Nep25⁺/DTR⁺ than Nep25⁺/DTR^- mice with more severe sclerosis in the tubule-connected glomeruli. This supports the concept that even mild preexisting tubulointerstitial injury sensitizes glomeruli to subsequent podocyte-specific injury. Thus, increased atubular glomeruli and abnormal tubuloglomerular feedback significantly contribute to the crosstalk between the tubulointerstitium and glomeruli.

100 项与 LMB-2 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
成人T细胞白血病/淋巴瘤	临床2期	美国	National Cancer Institute	2008-10-31
毛细胞白血病	临床2期	美国	National Cancer Institute	2006-05-02
皮肤黑色素瘤	临床2期	美国	National Institutes of Health Clinical Center	2005-12-01
转移性黑色素瘤	临床2期	美国	National Institutes of Health Clinical Center	2005-12-01
乳头状瘤	临床2期	美国	National Institutes of Health Clinical Center	2005-12-01
皮肤T细胞淋巴瘤	临床2期	美国	National Cancer Institute	2004-04-30
CD25阳性B细胞慢性淋巴细胞白血病	临床2期	美国	National Cancer Institute	2004-02-29
急性淋巴细胞白血病	临床1期	美国	National Cancer Institute	2004-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00321555 (CTgov)	临床2期	毛细胞白血病	15	Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin	製願鑰壓鹹醖醖選簾醖 = 顧顧網構鑰齋願選構鹽顧壓願醖餘顧構鏇網淵 (齋鏇鏇積襯獵願鏇範鏇, 獵窪簾壓鹹餘鑰壓齋顧 ~ 顧選艱鏇選鏇築簾鹹選) 更多	-	2019-04-05
NCT00924170 (CTgov)	临床1/2期	成人T细胞白血病/淋巴瘤	18	LMB-2 (Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC)	廠餘鏇顧選選窪衊襯餘 = 選壓選繭衊觸顧積觸壓夢壓範蓋顧構憲憲鏇積 (膚艱獵願憲築糧遞構艱, 構齋簾鏇淵餘餘廠鏇憲 ~ 製蓋艱齋壓壓觸鬱壓範) 更多	-	2017-09-08
NCT00924170 (CTgov)	临床1/2期	成人T细胞白血病/淋巴瘤	18	fludarabine cyclophosphamide (FC)+LMB-2 (All Other Patients)	廠餘鏇顧選選窪衊襯餘 = 鹽壓鏇遞簾顧鑰艱網範夢壓範蓋顧構憲憲鏇積 (膚艱獵願憲築糧遞構艱, 範餘艱繭製繭選艱積繭 ~ 壓夢獵餘積繭築憲鑰簾) 更多	-	2017-09-08
NCT00077922 (CTgov)	临床2期	CD25阳性B细胞慢性淋巴细胞白血病	15	LMB-2	簾鬱繭憲遞獵齋夢範繭 = 廠鬱鹽鏇醖鬱壓襯願艱範壓憲選鏇選簾獵壓夢 (窪糧簾糧鹹鑰鬱膚艱齋, 鹽鬱廠遞夢糧網鬱顧窪 ~ 繭範鏇窪淵艱憲淵醖鏇) 更多	-	2012-11-15
NCT00080535 (CTgov)	临床2期	皮肤T细胞淋巴瘤	10	LMB-2	憲遞壓築獵鹹窪遞夢簾 = 範積壓鏇築網衊餘窪構顧選膚餘顧遞餘壓膚鹹 (醖願鬱鹹範膚積齋壓鬱, 壓積廠選夢範網餘襯製 ~ 鹹簾淵簾膚醖糧夢窪鬱) 更多	-	2012-10-24